- Home
- TTNP vs IBO Comparison
TTNP vs IBO Comparison
Compare TTNP & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- IBO
- Stock Information
- Founded
- TTNP 1991
- IBO 2018
- Country
- TTNP United States
- IBO United States
- Employees
- TTNP N/A
- IBO N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- IBO
- Sector
- TTNP Health Care
- IBO
- Exchange
- TTNP Nasdaq
- IBO NYSE
- Market Cap
- TTNP 5.4M
- IBO 5.8M
- IPO Year
- TTNP 1996
- IBO 2024
- Fundamental
- Price
- TTNP $4.38
- IBO $0.69
- Analyst Decision
- TTNP
- IBO
- Analyst Count
- TTNP 0
- IBO 0
- Target Price
- TTNP N/A
- IBO N/A
- AVG Volume (30 Days)
- TTNP 17.4K
- IBO 635.2K
- Earning Date
- TTNP 08-14-2025
- IBO 08-23-2025
- Dividend Yield
- TTNP N/A
- IBO N/A
- EPS Growth
- TTNP N/A
- IBO N/A
- EPS
- TTNP N/A
- IBO N/A
- Revenue
- TTNP N/A
- IBO N/A
- Revenue This Year
- TTNP N/A
- IBO N/A
- Revenue Next Year
- TTNP N/A
- IBO N/A
- P/E Ratio
- TTNP N/A
- IBO N/A
- Revenue Growth
- TTNP N/A
- IBO N/A
- 52 Week Low
- TTNP $3.03
- IBO $0.36
- 52 Week High
- TTNP $14.80
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- TTNP 47.75
- IBO N/A
- Support Level
- TTNP $3.82
- IBO N/A
- Resistance Level
- TTNP $5.35
- IBO N/A
- Average True Range (ATR)
- TTNP 0.42
- IBO 0.00
- MACD
- TTNP -0.01
- IBO 0.00
- Stochastic Oscillator
- TTNP 36.60
- IBO 0.00
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.